Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUSJ3D)

Drug Name

BIIB-088 Drug Info

Synonyms

AGTC 501

Indication

Disease Entry	ICD 11	Status	REF
Retinitis pigmentosa	9B70	Phase 2/3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting X-linked retinitis pigmentosa GTPase regulator (RPGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIIB112	DMDY7RR	X-linked retinitis pigmentosa	9B70	Phase 3	[2]
AGTC-501	DMTS51C	Retinitis pigmentosa	9B70	Phase 1/2	[3]
AAV-RPGR	DM7TF49	Retinitis pigmentosa	9B70	Phase 1/2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
X-linked retinitis pigmentosa GTPase regulator (RPGR)	TTHBDA9	RPGR_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04850118) A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations. U.S. National Institutes of Health.
2	Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations. JAMA Ophthalmol. 2023 Mar 1;141(3):275-283.
3	ClinicalTrials.gov (NCT03316560) Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations. U.S. National Institutes of Health.
4	Clinical pipeline report, company report or official report of MeiraGTx.